Secondary Progressive Multiple Sclerosis

Neurology
7
Pipeline Programs
6
Companies
13
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
3
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
133%
Small Molecule
133%
Monoclonal Antibody
133%
+ 4 programs with unclassified modality

On Market (2)

Approved therapies currently available

Pfizer
MITOXANTRONE HYDROCHLORIDEApproved
mitoxantrone
Pfizer
injection2006
Biogen
TYSABRIApproved
natalizumab
Biogen
Integrin Receptor Antagonist [EPC]single-use2004

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
2 programs
1
BAF312Phase 41 trial
Blood DrawN/A5 trials
Active Trials
NCT03887520Completed49,001Est. Jul 2021
NCT02330965Completed36Est. Jul 2017
NCT02308904Completed59Est. Sep 2020
+3 more trials
Pfizer
PfizerNEW YORK, NY
1 program
1
1
MitoxantronePhase 31 trial
Active Trials
NCT00146159Terminated336
Biogen
BiogenCAMBRIDGE, MA
1 program
1
1
natalizumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT01416181Terminated889Est. Apr 2016
Zenas BioPharma
Zenas BioPharmaWALTHAM, MA
1 program
1
OrelabrutinibPhase 3Small Molecule1 trial
Active Trials
NCT07299019Not Yet Recruiting990Est. Jul 2030
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
dirucotidePhase 2/3Peptide1 trial
Active Trials
NCT00869726Completed596Est. May 2009
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Blood DrawN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
NovartisBAF312
NovartisBlood Draw
NovartisBlood Draw
NovartisBlood Draw
NovartisBlood Draw
Zenas BioPharmaOrelabrutinib
Biogennatalizumab
PfizerMitoxantrone
Eli Lilly and Companydirucotide
NovartisBlood Draw
NovartisBlood Draw
NovartisBlood Draw
NovartisBlood Draw

Clinical Trials (13)

Total enrollment: 53,783 patients across 13 trials

NCT04792567NovartisBAF312

Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)

Start: Apr 2021Est. completion: Aug 202241 patients
Phase 4Completed
NCT01562444NovartisBlood Draw

Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules

Start: Mar 2012Est. completion: Sep 2016206 patients
Phase 4Completed
NCT01106482NovartisBlood Draw

An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE

Start: May 2009Est. completion: May 2011126 patients
Phase 4Completed
NCT00452621NovartisBlood Draw

Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years

Start: Feb 2007235 patients
Phase 4Completed
NCT00310687NovartisBlood Draw

Persistence of Immune Response After Vaccination With MCC

Start: Oct 2004Est. completion: Dec 20051,244 patients
Phase 4Completed
NCT07299019Zenas BioPharmaOrelabrutinib

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

Start: Mar 2026Est. completion: Jul 2030990 patients
Phase 3Not Yet Recruiting
NCT01416181Biogennatalizumab

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis

Start: Sep 2011Est. completion: Apr 2016889 patients
Phase 3Terminated
NCT00146159PfizerMitoxantrone

Study Evaluating Mitoxantrone in Multiple Sclerosis

Start: Mar 2005336 patients
Phase 3Terminated
NCT00869726Eli Lilly and Companydirucotide

A Study for Patients With Secondary Progressive Multiple Sclerosis

Start: Dec 2004Est. completion: May 2009596 patients
Phase 2/3Completed
NCT00909363NovartisBlood Draw

Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients

Start: Jun 2009Est. completion: Jun 201724 patients
Phase 2Terminated
NCT03887520NovartisBlood Draw

Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)

Start: Nov 2018Est. completion: Jul 202149,001 patients
N/ACompleted
NCT02330965NovartisBlood Draw

Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis

Start: Dec 2014Est. completion: Jul 201736 patients
N/ACompleted
NCT02308904NovartisBlood Draw

Reproductive Capacity and Iron Burden in Thalassemia

Start: Jun 2013Est. completion: Sep 202059 patients
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
8h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
8h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
8h ago

Director of Finance

CoMind
London, UK
8h ago

Electronics Engineering Manager

CoMind
London, UK
8h ago

Director of Information Technology

Zavation Medical Products
9h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
6 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)